Related Experiment Video

Updated: Apr 3, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.4K

Mesothelioma: a systemic therapy clinical trials snapshot

Maurice Dungey1, Rushad Malhotra Mukhtyar2, Sean Dulloo1

  • 1NIHR Biomedical Research Centre & Experimental Cancer Medicine Centre, Division of Cancer Sciences, School of Medical Sciences, University of Leicester, Leicester, UK; Department of Oncology, University Hospitals of Leicester NHS Trust, Leicester, UK.

Trends in Cancer
|April 2, 2026
PubMed

Insights

New mesothelioma therapies are emerging from a deeper biological understanding, offering hope for improved survival. Research shows a growing number of clinical trials focusing on targeted drugs and immunotherapies.

Area of Science:

  • Oncology
  • Cancer Research
  • Translational Medicine

Background:

  • Mesothelioma survival rates have seen minimal improvement over the last 20 years.
  • Recent advances in understanding mesothelioma's biology are driving new therapeutic strategies.
  • There is a critical need for novel treatments to improve patient outcomes.

Purpose of the Study:

  • To review the current landscape of systemic therapy research for mesothelioma.
  • To forecast the future direction of drug development in mesothelioma over the next five years.
  • To identify emerging therapeutic trends and their potential impact.

Main Methods:

  • Conducted a census of active clinical trials for mesothelioma systemic therapies.
  • Categorized trials based on therapeutic approach: molecularly targeted, immunomodulation, and combination therapies.
  • Analyzed the proportion of trials within each category.

Main Results:

  • Identified 106 active trials involving systemic therapies for mesothelioma.
  • Molecularly targeted therapies constitute 19% (20 trials) of the research.
  • Immunomodulation (25%, 26 trials) and immunotherapy combined with antiangiogenic therapies (11%, 12 trials) are significant areas of investigation.

Conclusions:

  • The field of mesothelioma therapeutics is rapidly expanding with diverse innovative approaches.
  • The increasing number of clinical trials, particularly in targeted and immune-based therapies, suggests a promising future.
  • These advancements offer hope for significant improvements in mesothelioma patient life expectancy.
Keywords:
clinical trialsmesotheliomasystemic therapiestargeted treatment

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.8K
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.3K

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
955
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K